Related Experiment Video
Updated: Aug 10, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Leukemia-specific serum from a child showing an immunofluorescent pattern distinct from J-5 monoclonal antibody
E Azuma1, H Yamamoto, S Tanaka
1Department of Pediatrics, Mie University School of Medicine, Tsu, Mie-Ken, Japan.
Insights
A leukemia-specific antibody was found in children with acute lymphoblastic leukemia (ALL) treated with chemoimmunotherapy. This antibody targets a novel antigen distinct from the common ALL antigen (CD10).
Area of Science:
- Immunology
- Pediatric Oncology
Background:
- Chemoimmunotherapy, combining chemotherapy with biological response modifiers and irradiated leukemia cells, is used for acute lymphoblastic leukemia (ALL).
- A patient undergoing this treatment developed a serum containing a leukemia-specific antibody.
Purpose of the Study:
- To investigate the specificity and characteristics of the detected leukemia-specific antibody.
- To determine if this antibody targets an antigen different from the common ALL antigen (CALLA; CD10).
Main Methods:
- Detection of leukemia-specific human antibody in a child with ALL post-chemoimmunotherapy.
- Testing the serum's reactivity against ALL cells and normal cells using immunofluorescence.
- Comparative analysis with J-5 monoclonal antibody (anti-CALLA/CD10) on dual-stained ALL cell lines.
Main Results:
- The serum reacted with 89.5% of children with ALL (60/67) but not with normal cells.
- The ALL-specific serum exhibited a distinct immunofluorescent pattern compared to the J-5 antibody (anti-CD10).
- No blocking interaction was observed between the ALL-specific serum and J-5 antibody, indicating different target antigens.
Conclusions:
- The findings suggest the existence of an ALL-specific antigen(s) distinct from CALLA (CD10).
- This novel antigen(s) appears capable of eliciting a tumor-specific antibody response in patients with ALL.
- This discovery opens avenues for developing more targeted immunotherapies for ALL.
Abstract:
Leukemia-specific human antibody was detected in a child with acute lymphoblastic leukemia (ALL) treated with chemoimmunotherapy. Chemoimmunotherapy consists of standard chemotherapy and subcutaneous injections of irradiated ALL cells with a biological response modifier. This ALL-specific serum reacted in 60 out of 67 (89.5%) children with ALL and was not reactive with normal cells. Furthermore, this ALL-specific serum showed a different immunofluorescent pattern on dual staining as compared with J-5 monoclonal antibody directed for common ALL antigen (CALLA; CD10). J-5 did not block the reactivity of ALL-specific serum, and vice versa, when CD10-positive ALL cell lines were used as targets. These findings suggest the possibility that there exists an ALL-specific antigen(s) which is different from CALLA and that this antigen(s) elicits a tumor-specific antibody response.
